314130 — Genome&Company Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual balance sheet for Genome&Company, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	—	—	—	—	—
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	103,948	71,922	101,493	82,409	77,203
Net Total Accounts Receivable
Net Total Receivables	1,398	2,073	3,473	3,648	4,093
Total Inventory
Prepaid Expenses
Total Other Current Assets
Total Current Assets	111,280	81,777	116,909	97,050	91,928
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	4,271	16,475	21,526	34,624	27,870
Net Goodwill
Net Intangible Assets
Long Term Notes Receivable
Other Long Term Assets
Total Assets	120,883	137,216	172,997	162,060	147,335
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	3,008	9,826	11,141	28,231	29,812
Long Term Debt
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Minority Interest
Total Other Liabilities
Total Liabilities	9,171	44,483	75,701	99,632	99,024
Non Redeemable Preferred Stock
Common Stock
Additional Paid In Capital
Retained Earnings (Accumulated Deficit)
ESOP Debt Guarantee
Other Equity
Total Equity	111,711	92,733	97,296	62,428	48,311
Total Liabilities & Shareholders' Equity	120,883	137,216	172,997	162,060	147,335
Total Common Shares Outstanding
Total Preferred Shares Outstanding